Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03604601
Other study ID # recurrent laryngeal carcinoma
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2016
Est. completion date June 1, 2018

Study information

Verified date July 2018
Source First Affiliated Hospital, Sun Yat-Sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Early laryngeal cancer can be treatment by laser surgery or radiotherapy, intermediate and advanced laryngeal carcinoma mainly surgical treatment. Laryngeal cancer is at risk of recurrence after treatment, whether in surgery, laser or radiotherapy. The recurrence rate of laryngeal cancer is about 10% reported at home and abroad. Local pain, ulcers, breathing and eating difficulties caused by recurrent laryngeal cancer seriously reduce the quality of life of patients and seriously endanger their lives. Therefore, head and neck surgeons are required to make every effort to give them saving treatment in order to improve their quality of life. Prolong the patient's life.


Description:

medical records and extracted information including age, gender, initial treatment modality of glottis cancer, recurrence time, recurrence site, histopathology, tumor grade according to World Health Organization (WHO) grade and tumor stage. Stages were defined according to the American Joint Committee on Cancer (AJCC) staging system.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date June 1, 2018
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- more than 18 years,

- patients with recurrent glottic laryngeal squamous cell carcinoma undergoing salvage surgery

Exclusion Criteria:

- postoperative radiotherapy and chemotherapy

- loss to follow-up

Study Design


Intervention

Procedure:
salvage surgery
Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival (OS) The overall survival rate was calculated with Kaplan-Meier method. Follow up 5 years
See also
  Status Clinical Trial Phase
Suspended NCT04162873 - Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Phase 2